Table 5 Detailed information on patients and completed study phases

From: The treatment of spasticity with Δ9-tetrahydrocannabinol in persons with spinal cord injury

Age Sex Type   Phase 1 open label oral THC Phase 2 open label rectal THC Phase 3 Parallel study r, db, pc* Reasons for drop out
    0 1 8 43 1 8 43 1 8 43  
66 m Tetra x x x x x x x x x x  
43 m Para x x x x x x x x x x  
32 m Tetra x x x x x x x x x x  
42 m Para x x x x x x x x x x  
42 m Para x x x x (x) (x) (x) Reduced compliance
29 m Para x x x x x x x  
43 m Tetra x x x x x x x  
31 f Para x x x x x x x  
43 m Tetra x x x x x x x  
47 m Para x x x x x x x  
45 m Para x x x x x x x  
29 m Para x x x x x x x  
36 f Para x x x x x x x  
48 m Tetra x x x x x x x  
31 m Tetra x x x x Increased pain
73 m Tetra x x x Increased pain
29 m Tetra x x x Anxiety, increased pain
53 m Tetra x x No cause
36 m Tetra x x Anxiety
40 m Para x x Several psychological adverse effects
43 m Tetra x x Decreased attention and mood
19 m Para x (x) Several psychological adverse effects
51 m Tetra x x x x Apoplexia
63 m Tetra x x x x Pain, decreased compliance
51 m Tetra x (x) (x) pain
    25 22 17 15 8 8 7 13 13 13  
  1. x Data complete
  2. (x) Data incomplete
  3. — No data available
  4. r=randomized, db=double-blind, pc=placebo-controlled